Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Dec 1;16(12):e0260063.
doi: 10.1371/journal.pone.0260063. eCollection 2021.

The worldwide burden of HIV in transgender individuals: An updated systematic review and meta-analysis

Affiliations
Meta-Analysis

The worldwide burden of HIV in transgender individuals: An updated systematic review and meta-analysis

Sarah E Stutterheim et al. PLoS One. .

Abstract

Introduction: Transgender individuals are at risk for HIV. HIV risks are dynamic and there have been substantial changes in HIV prevention (e.g., pre-exposure prophylaxis [PrEP]). It is thus time to revisit HIV prevalence and burden among transgender individuals. The objective of this systematic review and meta-analysis was thus to examine worldwide prevalence and burden of HIV over the course of the epidemic among trans feminine and trans masculine individuals.

Methods: We conducted an updated systematic review by searching PsycINFO, PubMed, Web of Science, and Google Scholar, for studies of any research design published in in a peer-reviewed journal in any language that reported HIV prevalence among transgender individuals published between January 2000 and January 2019. Two independent reviewers extracted the data and assessed methodological quality. We then conducted a meta-analysis, using random-effects modelling, to ascertain standardized prevalence and the relative burden of HIV carried by transgender individuals by country and year of data collection, and then by geographic region. We additionally explored the impact of sampling methods and pre-exposure prophylaxis (PrEP).

Results: Based on 98 studies, overall standardized HIV prevalence over the course of the epidemic, based on weights from each country by year, was 19.9% (95% CI 14.7% - 25.1%) for trans feminine individuals (n = 48,604) and 2.56% (95% CI 0.0% - 5.9%) for trans masculine individuals (n = 6460). Overall OR for HIV infection, compared with individuals over age 15, was 66.0 (95% CI 51.4-84.8) for trans feminine individuals and 6.8 (95% CI 3.6-13.1) for trans masculine individuals. Prevalence varied by geographic region (13.5% - 29.9%) and sampling method (5.4% - 37.8%). Lastly, PrEP effects on prevalence could not be established.

Conclusion: Trans feminine and trans masculine individuals are disproportionately burdened by HIV. Their unique prevention and care needs should be comprehensively addressed. Future research should further investigate the impact of sampling methods on HIV prevalence, and monitor the potential impact of PrEP.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. PRISMA flow chart describing the study selection process.
Fig 2
Fig 2. Forest plot of HIV prevalence in trans feminine individuals compared to all adults (age 15+).
The scale on the x-axis is log odds ratio. The percentages indicate the weight of each country by year within the meta-analysis. The numbers in the right column are the log odds ratios including their confidence intervals. We converted these log odds ratios into odds ratios, as described in Table 2.
Fig 3
Fig 3. Forest plot of HIV prevalence in trans masculine individuals compared to all adults (age 15+).
The scale on the x-axis is log odds ratio. The percentages indicate the weight of each country by year within the meta-analysis. The numbers in the right column are the log odds ratios including their confidence intervals. We converted these log odds ratios into odds ratios, as described in Table 3.
Fig 4
Fig 4. Forest plot of HIV prevalence in trans feminine individuals in the USA compared to all adults (age 15+) in the USA.
The 10 country-year including 18 studies above the line are studies where data were collected prior to the introduction of PrEP (2012). The 3 country-year including 6 studies below the line are studies where data were collected after the introduction of PrEP. The scale on the x-axis is log odds ratio. The percentages indicate the weight of each sample within the meta-analysis. The numbers in the right column are the log odds ratios including their confidence intervals.

References

    1. Reisner SL, Murchison GR. A global research synthesis of HIV and STI biobehavioural risks in female-to-male transgender adults. Glob Public Heal. 2016/01/21. 2016;11: 866–887. doi: 10.1080/17441692.2015.1134613 - DOI - PMC - PubMed
    1. Melendez RM, Bonem LA, Sember R. On Bodies and Research: Transgender Issues in Health and HIV Research Articles. Sex Res Soc Policy A J NSRC. 2006;3: 21–38. doi: 10.1525/srsp.2006.3.4.21 - DOI
    1. World Health Organization W. Policy brief: Transgender people and HIV. Geneva, Switzerland; 2015. Available: https://www.who.int/hiv/pub/transgender/transgender-hiv-policy/en/.
    1. Baral SD, Poteat T, Stromdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13: 214–222. doi: 10.1016/S1473-3099(12)70315-8 - DOI - PubMed
    1. Poteat T, Scheim A, Xavier J, Reisner S, Baral S. Global Epidemiology of HIV Infection and Related Syndemics Affecting Transgender People. J Acquir Immune Defic Syndr. 2016/07/20. 2016;72 Suppl 3: S210–9. doi: 10.1097/QAI.0000000000001087 - DOI - PMC - PubMed

Publication types

MeSH terms